Khayal Tamer I 4

Accession 0000950170-24-112394

CIK 0001756262other

View on SEC.gov Company Profile

Filed

Oct 2, 8:00 PM ET

Accepted

Oct 3, 4:30 PM ET

Size

29.1 KB

Accession

0000950170-24-112394

Insider Transaction Report

Form 4

Period: 2024-10-01

TransMedics Group, Inc.TMDX

Khayal Tamer I

Chief Commercial Officer

Transactions

Sale
Common Stock
2024-10-01$151.20/sh−80$12,096→ 21,077 total
Sale
Common Stock
2024-10-01$152.28/sh−80$12,182→ 20,997 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-10-01−1,458→ 7,292 total
Exercise: $38.46Exp: 2031-02-24→ Common Stock (1,458 underlying)
Sale
Common Stock
2024-10-01$146.90/sh−900$132,210→ 22,078 total
Sale
Common Stock
2024-10-01$147.98/sh−80$11,838→ 21,998 total
Sale
Common Stock
2024-10-01$149.59/sh−523$78,236→ 21,475 total
Sale
Common Stock
2024-10-01$150.38/sh−318$47,821→ 21,157 total
Sale
Common Stock
2024-10-01$153.75/sh−20$3,075→ 20,977 total
Exercise/Conversion
Common Stock
2024-10-01$66.10/sh+417$27,564→ 22,718 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-10-01−1,083→ 18,417 total
Exercise: $13.28Exp: 2032-02-22→ Common Stock (1,083 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-10-01−417→ 12,098 total
Exercise: $66.10Exp: 2033-02-20→ Common Stock (417 underlying)
Exercise/Conversion
Common Stock
2024-10-01$38.46/sh+1,458$56,075→ 22,301 total
Exercise/Conversion
Common Stock
2024-10-01$13.28/sh+1,083$14,382→ 23,801 total
Sale
Common Stock
2024-10-01$146.15/sh−823$120,281→ 22,978 total
Sale
Common Stock
2024-10-01$154.86/sh−134$20,751→ 20,843 total

Footnotes (9)

[F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.
[F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $145.54 to $146.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F3]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $146.555 to $147.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F4]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $149.06 to $150.005, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F5]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $150.07 to $150.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F6]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $154.785 to $154.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F7]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 24, 2025.
[F8]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 20, 2027.
[F9]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

TransMedics Group, Inc.

CIK 0001756262

→

Entity typeother

Related Parties

filerCIK 0001430462

Filing Metadata

Form type: 4
Filed: Oct 2, 8:00 PM ET
Accepted: Oct 3, 4:30 PM ET
Size: 29.1 KB

View on SEC.gov